Related Experiment Video
Updated: Jul 8, 2026
Establishment and Characterization of Patient-derived Gastric Organoids from Biopsies of Benign Gastric Body and Antral Epithelium
Published on: January 26, 2024
Gastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine
Abstract:
Significant advances in the treatment of localized gastric cancer have been achieved through early screening, improved diagnostic techniques, surgeries, and adjuvant chemotherapy; however, the need for personalized treatment remains under debate. This review highlights the use of gastric cancer organoid (GCO) models to study cancer mechanisms, drug discovery, and precision medicine, focusing on their ability to simulate the tumor microenvironment, reveal cell heterogeneity, and assess drug responses. In particular, the integration of CRISPR/Cas9 gene editing with GCOs provides a powerful platforms for identifying new drug targets and supporting clinical applications in precision medicine. This review also explores the potential of these organoids in future research, particularly in optimizing treatment strategies and developing personalized therapies, thus offering new directions for precision treatment of gastric cancer.
Insights
Gastric cancer organoid (GCO) models offer a powerful platform for studying cancer mechanisms and drug discovery. Integrating CRISPR/Cas9 gene editing with GCOs advances precision medicine for gastric cancer.
Area of Science:
- Oncology
- Genetics
- Biotechnology
Background:
- Localized gastric cancer treatment has advanced, but personalized approaches require further investigation.
- Current models struggle to fully replicate the tumor microenvironment and cellular heterogeneity of gastric cancer.
Purpose of the Study:
- To review the utility of gastric cancer organoid (GCO) models in understanding cancer biology and advancing precision medicine.
- To highlight the integration of CRISPR/Cas9 gene editing with GCOs for drug target identification and clinical applications.
Main Methods:
- Review of current literature on gastric cancer organoid models.
- Analysis of GCO capabilities in simulating tumor microenvironment and cell heterogeneity.
- Exploration of CRISPR/Cas9 gene editing applications within GCO platforms.
Main Results:
- GCO models effectively simulate the tumor microenvironment and reveal cellular heterogeneity.
- CRISPR/Cas9-integrated GCOs serve as powerful platforms for drug discovery and target identification.
- GCOs demonstrate significant potential in assessing drug responses and optimizing treatment strategies.
Conclusions:
- Gastric cancer organoid models are crucial tools for advancing precision medicine in gastric cancer.
- The combination of GCOs and CRISPR/Cas9 offers new avenues for developing personalized therapies and improving patient outcomes.
